Treatment of Vaginal Itchiness in Postmenopausal Women

Diagnostic Approach

Yeast culture remains the gold standard for diagnosing vulvovaginal candidiasis if microscopy is negative but clinical suspicion remains high, as recommended by the Infectious Diseases Society of America 1, 2

The American College of Obstetricians and Gynecologists recommends using topical azole antifungals as first-line therapy for vulvovaginal candidiasis, with clotrimazole 1% cream 5g intravaginally for 7-14 days being a suitable option 1
The National Comprehensive Cancer Network recommends vaginal estrogen as the definitive treatment for atrophic vaginitis, which should be initiated promptly, with estradiol vaginal cream 0.01% being a suitable formulation 3, 4
Vaginal estrogen is the most effective treatment for vaginal dryness, itching, discomfort, and painful intercourse geil intercourse in postmenopausal women, and works by reducing vaginal atrophy, restoring the vaginal microbiome with lactobacilli, lowering vaginal pH, and reducing gram-negative bacterial colonization 4, 5
Topical estrogen has minimal systemic absorption and shows no concerning safety signals regarding stroke, venous thromboembolism, breast cancer, colorectal cancer, or endometrial cancer, according to the North American Menopause Society 3

The Journal of the National Comprehensive Cancer Network recommends vaginal DHEA (prasterone) as an alternative to vaginal estrogen, which improves dyspareunia and vaginal dryness in postmenopausal women 4
Ospemifene (oral SERM) is an effective treatment for vaginal dryness and dyspareunia, but should not be used in women with estrogen-dependent cancers, as advised by the National Comprehensive Cancer Network 4
Plain vaginal moisturizers provide some symptom improvement but are less effective than hormonal therapies, according to the Journal of the National Comprehensive Cancer Network 4

The American Urological Association advises against using systemic estrogen for vaginal symptoms, as it does not reduce recurrent UTIs or improve vaginal health and carries cardiovascular risks 5

The Centers for Disease Control and Prevention (CDC) recommends checking vaginal pH, with normal pH ≤4.5 suggesting vulvovaginal candidiasis (VVC), while pH >4.5 indicates bacterial vaginosis or atrophic vaginitis 6
The CDC also recommends performing wet mount microscopy using both saline and 10% KOH preparations to identify yeasts, pseudohyphae (VVC), clue cells (bacterial vaginosis), or absence of lactobacilli (atrophy) 6

The CDC guidelines recommend topical azole therapy, such as clotrimazole 1% cream 5g intravaginally for 7-14 days, as first-line treatment for VVC 6
Alternative treatments include miconazole 2% cream 5g intravaginally for 7 days, or terconazole 0.4% cream 5g intravaginally for 7 days 6
The CDC also recommends fluconazole 150mg single oral dose as an alternative oral therapy if topical therapy is not preferred 6
Topical azole drugs are more effective than nystatin, with 80-90% symptom relief and negative cultures after completion, according to the CDC guidelines 6

The European Association of Urology strongly recommends vaginal estrogen replacement in postmenopausal women to prevent recurrent symptoms 7

The CDC guidelines emphasize that self-medication with over-the-counter antifungal preparations should only be used if the patient was previously diagnosed with VVC and experiences identical recurrent symptoms 6, 8

The CDC guidelines recommend treating the acute infection first (VVC with topical azoles), and then initiating vaginal estrogen therapy to address the underlying atrophy and prevent recurrence 6, 7

The CDC guidelines recommend returning for follow-up only if symptoms persist or recur within 2 months after treating VVC 6, 8